For the Inventor, By the Inventor

Enter assignee name

Ghaziabad, India

Dabur Research Foundation

Calculating rank

USPTO Granted Patents = 29

% Expired Patents = 37.9

Forward Citations = 215

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Rama Mukherjee (17 out of 25 patents)

Manu Jaggi (17 out of 22 patents)

Anand C Burman (16 out of 24 patents)

4. Sudhanand Prasad (11 out of 15 patents)

5. Anu T Singh (10 out of 13 patents)

6. Sunder Ramadoss (9 out of 9 patents)

7. Archna Mathur (6 out of 6 patents)

8. Dhiraj Khattar (3 out of 13 patents)

9. Anand Vardhan (3 out of 4 patents)

10. Rajan Sharma (3 out of 3 patents)

11. Mohammad Jamshed Ahmad Siddiqui (3 out of 3 patents)

12. Kamal K Kapoor (3 out of 3 patents)

13. Chandra Kant Katiyar (3 out of 3 patents)

14. Gautam R Desiraju (2 out of 8 patents)

15. Mukesh Kumar (2 out of 6 patents)

Core Competencies:

Cyclopentenone Derivatives

Peptide Analogs

Vasoactive Intestinal Peptide

Betulinic Acid Derivatives

Anticancer Agents

Paclitaxel Derivatives

Synthetic Bioactive Peptides

Antiangiogenic Activity

Drug Resistant Infections

Furanoid Sugar Amino Acids

Carvedilol Isomers

Methylglyoxal Conjugates

29 patents: Sort by Forward Citations

1. 7179937 - Cyclopentenone derivatives for cancer therapy (2007-02-20),

2. 7173006 - Drug comprising synthetic peptide analogs for the treatment of cancer (2007-02-06),

3. 7094755 - Vasoactive intestinal peptide analogs (2006-08-22),

4. 7060678 - Peptides comprising furanoid sugar amino acids for the treatment of cancer (2006-06-13),

5. 6989371 - Bombesin analogs for treatment of cancer (2006-01-24),

6. 6949557 - Hydroanthracene based compounds as anticancer agents (2005-09-27),

7. 6949513 - Polypeptides of covalently linked synthetic bioactive peptide analog(s) for treatment of cancer (2005-09-27),

8. 6828304 - Peptides for treatment of cancer (2004-12-07),

9. 6670345 - Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid (2003-12-30),

10. 6656970 - Method and compositions for solubilization of pentacyclic triterpenes (2003-12-02),

11. 6632832 - Anti-cancer activity of carvedilol and its isomers (2003-10-14),

12. 6613793 - Anticancer activity of imino acid conjugates or methylglyoxal (2003-09-02),

13. 6608174 - Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy (2003-08-19),

14. 6599541 - Composition for treatment of drug resistant bacterial infections and a method of treating drug resistant bacterial infections (2003-07-29),

15. 6596755 - Oral formulation of methylglyoxal and its imino acid conjugates for human use (2003-07-22),

Company Overview

Dabur Research Foundation, based in Ghaziabad, India, is dedicated to advancing research and development in the fields of natural products and herbal formulations. The organization specializes in the exploration of traditional medicine and its integration into modern healthcare solutions. With a focus on innovation, Dabur Research Foundation aims to enhance the efficacy and safety of herbal products, contributing to the wellness and health sectors through scientific validation and technological advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

29 Patents

#1 in Ghaziabad

#71 in India

#22,570 in the World

Ghaziabad, India

Dabur Research Foundation

Forward Citations = 215

49 inventors:

Rama Mukherjee (17 out of 25 patents)

Manu Jaggi (17 out of 22 patents)

Anand C Burman (16 out of 24 patents)

4. Sudhanand Prasad (11 out of 15 patents)

5. Anu T Singh (10 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dabur Research Foundation. Retrieved from https://idiyas.com/company/dabur-research-foundation

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…